Vinblastine apparently binds to microtubular proteins (tubulin) in the mitotic spindle, thereby preventing cell division during metaphase. It also interferes with amino acid metabolism by inhibiting glutamic acid utilization and preventing purine synthesis, citric acid cycle, and urea formation.
Vinblastine may be employed in the treatment of lymphomas, carcinomas, mastocytomas, and splenic tumors in small animals. It is more effective than vincristine in the treatment of canine mast cell tumors.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
Vinblastine 是窄治療範圍、僅 IV 的細胞毒性危害藥。犬肥大細胞瘤、犬膀胱移行上皮癌與貓 COVP 的研究方案在腫瘤、劑量、間隔、併藥與毒性調整上皆不同；不得攤平成通用犬貓計算器。所有自動計算、處方與飼主劑量均封鎖，只保留不可執行的 protocol 證據卡。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。